In a phase 2 study of INCB050465 plus ruxolitinib in patients with myelofibrosis who previously had a suboptimal or loss of response to ruxolitinib alone, the combination demonstrated preliminary efficacy, and the daily 8-week/then once per week dosing regimen had a better toxicity profile than other PI3K inhibitors have shown.
Blood (ASH Abstract)